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New Positive Inotropic Agents
Syed M. Jafri, MD,* and James A. Bristol, PhD^

Current therapy for heart failure remains inadequate. New positive inotropic agents that augment
myocardial contractility have been introduced. The positive inotropic effects ofthese nonglycoside,
nonsympathomimetic agents are due, at least in part, to inhibition of cardiac phosphodiesterase
activity and hence to an increase in myocardial cyclic AMP levels. These agents also have vasodilator
properties through their effects on the enzyme phosphodiesterase in the vascular smooth muscle.
Recent developments in the preclinical pharmacology, mechanism of action, and clinical experience
with these new inotrope vasodilators are presented in this review. The role these drugs will play in
revising our therapeutic strategy in congestive heart failure remains to be defined. (Henry Ford H osp
MedJ 1986;34:188-92)

urrent therapy for heart failure is aimed at improving
myocardial contractility by reducing volume overload or
systemic vascular resistance. Digitalis glycosides and sympathomimetic drugs have long been used to improve the contractile state of the myocardium. The efficacy of chronic digitalis
therapy in patients with heart failure and sinus rhythm has recendy been challenged (1), and sympathomimetic agents are
limited by their chronotropic side-effects and their need for intravenous administration,
The requirements of a clinically useful inotropic agent have
been summarized in a recent review by Braunwald and Colucci
(2). An ideal agent should produce hemodynamic improvement
(both at rest and with exercise), have persistent clinical and hemodynamic effects, be well tolerated and relatively free of sideeffects, and prolong survival. No such agent cunently exists.
Several "new" positive inotropic agents are undergoing trials,
including a new class of nonglycoside, nonsympathomimetic
dmgs.
Most inotropic agents stimulate myocardial contractility by
either inhibition of Na + /K+ ATPase, activation of membranebound adenylcyclase, or inhibition of cyclic AMP phosphodiesterase (3). Recently, a new class of dmgs which increase
calcium sensitivity of the myofilaments partly by increasing the
affinity of troponin to calcium has been described (4). This review focuses primarily on one class of these newer inotropic
agents that have phosphodiesterase inhibitory properties and potential as therapeutic agents in the management of patients with
heart failure.

C

Preclinical Evaluation of Positive Inotropic
Efficacy of Phosphodiesterase Inhibitors
The newer agents being developed for treatment of heart
failure generally fall into three main classes of chemical stmcture: 2(lH)-pyridones, also referred to as bipyridines, which
include amrinone and milrinone; 2H-imidazol-2-ones which
include enoximone (MDL 17,043) and piroximone (MDL
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19,205); and 4,5-dihydro-3(2H)-pyridazinones of which imazodan (CI-914) and CI-930 are the most prominent examples.
Thorough characterizadon of preclinical pharmacology including positive inotropic efficacy and studies designed to elucidate
the mechanism of action have been reported for these agents and
are summarized here briefly.
Amrinone and milrinone
The preclinical pharmacology of amrinone and milrinone
has been studied extensively (5,6). The two agents have similar properties, with milrinone characterized as 10 to 30 dmes
more potent than amrinone. The cardiovascular responses to
amrinone have been evaluated in vitro and in vivo in dogs, cats,
monkeys, and man. In vitro treatment of isolated cat atria
and papillary muscles with amrinone (3 to 1000 p-g/mL) produces dose-dependent increases in atrial and papillary muscledeveloped tension (5). Intravenous administration of 1 to 10
mg/kg of amrinone to anesthetized dogs produces dose-related
increases in contractility (dP/dtmax), slight increases in heart
rate, and slight decreases in blood pressure (5). Oral doses of
amrinone to conscious dogs (1 to 10 mg/kg) produce an increase
in cardiac contractile force with a long duration of acdon. Similarly, intravenous administration of 0.01 to 0.1 mg/kg of
milrinone to anesthetized dogs produces significant changes in
contractility (23% to 87%), whereas heart rate and blood pressure are relatively unaffected (6). Oral doses of milrinone (0.1 to
1.0 mg/kg) to conscious dogs produce a dose-related increase in
contractility.
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Table 1
Positive Inotropic Effects of New Agents for
Congestive Heart Failure in Conscious Dogs
Compound (Reference)
Amrinone ( I I )
Milrinone (11)
Enoximone (7)
Piroximone (8)
Imazodan (11)
CI-930 (II)

Dose (mg/kg)

% Increase Contractility

10.0
1.0
10.0
3.0

45
45
49
54
40
42

1.0
0.1

Enoximone and piroximone
The in vivo and in vitro pharmacology for enoximone and piroximone have been extensively evaluated (7,8). In the anesthetized dog, enoximone (7) and piroximone (8) (0.1 to 10 mg/kg)
result in a dose-related positive inotropic response accompanied
by a minor increase in heart rate and a minor decrease in blood
pressure. These hemodynamic changes were not altered by
alpha or beta blockade (9,10). Both compounds lead to a
vasodilatory response in the canine pump-perfused hindlimb
preparation. This acdon was not attenuated by alpha, beta, cholinergic, or histaminergic blockade, thus indicating that these
compounds produce vasorelaxation by a direct mechanism
(9,10). Oral administradon of enoximone (7) and piroximone (8)
to conscious dogs produces a dose-related increase in contractility, with piroximone being approximately three times as potent as enoximone (Table I).
Imazodan (CI-914) and CI-930
Studies on imazodan (11-14) and CI-930 (11) have been reported. Imazodan has a dose-related increase in positive inotropic activity in excised guinea pig atrial and rabbit papillary
muscle preparations. In anesthetized dogs, imazodan (0.001 to
1.0 mg/kg intravenously) increases myocardial contractility of
10% to 150% and decreases aortic blood pressure up to 31%.
Minimal heart rate changes occuned relative to the positive inotropic responses. The positive inotropic responses were not
blocked by propranolol. Forelimb perfusion studies in the anesthetized dog showed that imazodan also produces a direct peripheral vasodilator action. CI-930 has similar actions to those
of imazodan with an approximate fivefold to tenfold increase
in potency. Table I describes the relative oral potencies of
amrinone, milrinone, enoximone, piroximone, imazodan, and
CI-930 in the conscious dog (7,8,11). As evident from these
data, CI-930 is the most potent of these agents.
Mechanism of action
Since the pioneering work of Sutherland and Rail (15), who
first described the role of cyclic AMP as the "second messenger" which mediates the response of cells to hormones and
neurotransmitters, research into many aspects of cyclic nucleotide metabolism has expanded significantly. Regarding
potential biochemical mechanisms to augment myocardial contractility, phosphodiesterase inhibition remains an adractive
mechanism. Inhibition of cAMP phosphodiesterase within the
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Table 2
Inhibition of Guinea Pig Cardiac Phosphodiesterase by
New Cardiotonic Agents: Theophylline and Papaverine (14)
IC50 (^jtmoI/L)

Agent
Amrinone
Milrinone
Enoximone
Imazodan
CI-930
Papaverine
Theophylline

PDEI
cAMP
cGMP
>1000
>1000
310
340
>1000
>I0OO
>I000
>I0OO
820
>IOOO
24
27
230
310

PDE
cAMP
720
22U
860
750
400
6.0
210

II
cGMP
580
200
450
530
360
5.1
170

PDE III
cAMP
46
2.5
14
8.2
2.9
3.8
340

myocardial cell and the consequent increase in intracellular
cAMP serve to open the calcium slow channel. The increased
intracellular concentration of calcium entering from the slow
channel causes the release of additional calcium stored in the
sarcoplasmic reticulum, which in tum initiates contraction via
interaction with the contractile protein, troponin C.
Recently, several different molecular forms (isozymes) of
phosphodiesterase have been separated from tissues of several
species and characterized kinetically (16). In cardiac tissue isolated from guinea pigs, three molecular forms of phosphodiesterase exist.
Classical inhibitors of phosphodiesterase (PDE), ie,
theophylline, isobutylmethylxanthine (IBMX), and papaverine, inhibit nonselecdvely all three forms of PDE. Of considerable interest and significance was the discovery that the new cardiotonic agents described in this review inhibit selectively the
cyclic AMP specific form (PDE III) relative to their effects on
PDE 1 and 11. The effects of several cardiotonics on inhibition of
cardiac PDE 111 are compared in Table 2 (17).
By applying a linear regression analysis, an excellent conelation between inhibition of PDE III in vitro and positive inotropic
activity in vivo across several stmctural classes was identified.
This conelation strongly suggests that inhibition of cardiac PDE
111 represents a principal component of the positive inotropic action of these classes of compounds (11). Furthermore, all of the
newer agents described possess vascular relaxant effects which
may be associated with inhibition of one of the molecular forms
of PDE present in vascular tissue (17).

Clinical Experience with
Phosphodiesterase Inhibitors
Amrinone and milrinone
Amrinone, a bipyridine derivative, the prototype of this
generation of inotropic agents, has recently been approved for
intravenous use in patients with congestive heart failure. Both
intravenous and oral forms of the dmg have been shown to improve hemodynamics and myocardial energetics at rest and with
exercise (18,19). Parenteral amrinone has hemodynamic effects
similar to dobutamine in patients with congestive heart failure
(20). While the hemodynamic effects are sustained during
amrinone infusion, tachyphylaxis seems to occur after eight to
24 hours of dobutamine infusion. Comparison of dobutamine.
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dopamine, and amrinone showed that amrinone caused less
chronotropic response than dopamine (21).
The inidal intravenous dose of amrinone is 0.5 to 1.5 mg/kg,
given as a bolus, followed by an infusion of between 5 to 10
mg/kg/min, titrated to the hemodynamic response. The onset of
action is rapid, occuning within ten minutes; however, its halflife is three to six hours which may be a disadvantage in some
clinical settings of acute heart failure. Potential side-effects include hypotension, reversible thrombocytopenia, fever, gastrointestinal intolerance, and hepatotoxicity (22). The initial enthusiasm for the use of oral amrinone for long-term therapy has
diminished because the results of double-blind, placebo-controlled studies failed to show significant benefits in exercise capacity or cardiac function (23,24).
Milrinone is another bipyridine derivative, with ten to 30
times the potency of amrinone. Several studies have demonstrated its beneficial hemodynamic and clinical effects (25).
Milrinone is better tolerated than amrinone and does not have the
hematopoietic side-effects. Since it is largely excreted through
the kidneys, milrinone should be used with caution in patients
with renal dysfunction. Bairn et al (26) have reported their
experience of long-term therapy with milrinone in 100 patients.
Side-effects leading to drug withdrawal including headache,
muscular weakness, insomnia, and increased ventricular arrhythmias occurred in only 4% of the patients. The drug was
well tolerated with hemodynamic and clinical improvement;
however, the mortality rate was 63% after one year of therapy.
Advanced funcdonal class, impaired renal function, reduced
ejection fraction, and the presence of nonsustained ventricular
tachycardia on 24 hr holler monitoring were some ofthe predictors for early mortality. In a study of 20 patients on chronic
milrinone therapy. Holmes et al (27) noted increased complex
ventricular anhythmias in 40% of the patients. Further studies
comparing placebo to milrinone are needed to characterize the
utility of this dmg.

Enoximone (MDL 17,043) and piroximone (MDL 19,205)
MDL 17,043 (enoximone) is an imidazole derivadve with
similar hemodynamic effects to those of amrinone and
milrinone (28). The hemodynamic effect of intravenous MDL
17,043 in patients is comparable to dobutamine except that
dobutamine has a slightly higher chronotropic effect (29). Oral
MDL 17,043 is rapidly absorbed with an elimination half-life of
about 20 hours. The dmg is well tolerated during follow-up, and
side-effects include gastrointestinal distress, headache,
agranulocytosis, ventricular ectopy, and abnormal liver function
tests (28). No improvement in survival was demonstrated in patients treated with this dmg despite the acute hemodynamic benefit and symptom palliation.
Piroximone (MDL 19,205) also shows favorable hemodynamic effects when administered acutely (30). Petein et al
(31) noted that despite the acute hemodynamic effects and shortterm clinical benefit, long-term administration of oral MDL
19,205 was not effecdve in symptom palliation. The apparent
lack of favorable long-term effect may be related to the patient
population or dosage used or may reflect the general use of these
"new" inotropic agents.
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Imazodan (CI-914) and CI-930
We have recendy reported the hemodynamic effects of a new
type 111 phosphodiesterase inhibitor, CI-914, in 13 patients
with severe congestive heart failure (32). CI-914 is a dihydropyridazinone derivative and in vitro has ten times the potency of
amrinone (33). It shows only slight stimulation of calcium release and has no direct effect on sarcoplasmic reticulum, mitochondrial function, adenylcyclase, or on NA + /K +ATPase activity (33).
An increase in cardiac index of 26% (P < 0.01), a decrease in
pulmonary wedge pressure of 21% (P < 0.001), a right atrial
pressure of 30% (P < 0.02), and systemic vascular resistance of
23% (P < 0.02) occuned following intravenous CI-914 administration without significant changes in heart rate, mean blood
pressure, and pulmonary vascular resistance. Similar changes
were noted with oral administration of the drug. Peak plasma
concentration after oral dosage occuned 2.3 ± 2.2 hours after
ingestion; however, the elimination of this drug appears to be
nonlinear. The hemodynamic effects of the dmg were sustained
ten to 12 hours after oral administration (Figure) and appear to
be related to the combined effect of the dmg as well as its active
N-acetyl metabolite (17).
Seven ofthe 13 patients who received long-term therapy for 12
weeks or more showed improvement in functional class and exercise capacity, although no significant change in left ventricular
ejection fraction was seen. Three of these patients remain on
therapy after 20 months and have had improvement in symptoms. The drug was well tolerated without gastrointestinal,
hematopoietic, and hepatic side-effects. One patient developed
symptomatic ventricular tachycardia while on the dmg and was
treated with antianhythmic agents. Although the CI-914 agent
has some promising characteristics as an inotrope, further studies are required to elucidate the exact mechanism of action and
efficacy.
CI-930 is also a dihydro-pyridazinone derivative, a structural analogue of CI-914, except for the presence ofan additional methyl group on position five of the pyridazinone ring. It
is three to five times more potent in vitro than CI-914 (11). We
studied the hemodynamic response to this dmg in ten patients
with severe congestive heart failure (34). Significant acute
hemodynamic effects with a 35% increase in cardiac index
(P < 0.002), a 35% decrease in pulmonary wedge pressure
(P < 0.05), a 40% decrease in right atrial pressure (P < 0.05),
and a 26% decrease in systemic vascular resistance (P < 0.05)
occuned 15 minutes following intravenous CI-930. Similar effects were noted after oral CI-930, and the hemodynamic effects
were sustained 12 to 18 hours after the oral dose. The sustained
hemodynamic effects of this dmg are most likely a result of an
active N-acetyl metabolite (35) rather than a direct action of the
dmg because its plasma half-life was only 1.1 to 6.4 hours in the
patients studied. The drug was well tolerated and has potential
for treatment of heart failure. The role of this new class of inotropic agents in the management of patients with heart failure
needs to be defined. Although broadly classified as phosphodiesterase inhibitors, these inotropic agents differ significantly
from the classic PDE inhibitors in that they selectively inhibit
the PDE isoenzyme III.
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Several open label studies of the new agents claim superiority
in symptom palliation for patients treated but inadequately controlled with conventional dmg therapy (18,25). However, results
of the only reported placebo-controlled trial with amrinone did
not show significant improvement in exercise capacity or cardiac
function (23,24). Evidently cardiac deterioration continues despite the hemodynamic and clinical benefits during long-term
therapy (15). Theoretical concems have been raised about the rationale for stimulating the failing myocardium (36). Whether
these agents accelerate disease progression by exhausting the
myocardial energy stores or adversely influence survival by aggravating ventricular anhythmias is unclear The adverse effects
may be related to an exacerbation of ischemia with use of these
agents or may be due to the direct toxic effects of elevated cyclic
AMP levels (37). These concerns are best addressed in careful.

long-term, placebo-controlled trials foreach of these agents.
These trials are cunently underway, and the results will soon be
reported. These drugs are sdll investigational and need to be
tested further as potendal therapeutic agents in the management
of patients with heart failure.
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